The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study with expansion cohorts of cabozantinib (C) + abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study.
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Therapeutics; Leuchemix
Consulting or Advisory Role - Astellas Pharma; Bayer; BIND Biosciences; Genentech; Janssen; Sanofi
Research Funding - Exelixis (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix
 
Kathryn P. Gray
Stock and Other Ownership Interests - DYAX
 
Lauren Christine Harshman
Consulting or Advisory Role - Bristol-Myers Squibb; Dendreon; Medivation/Astellas; NCCN; Pfizer; PlatformQ Health
Research Funding - Bayer; Medivation/Astellas
 
Mary-Ellen Taplin
Honoraria - Bayer; Dendreon; Janssen-Ortho; Medivation; Tokai Pharmaceuticals
Consulting or Advisory Role - Bayer; Best Doctors, Inc; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen-Ortho; Medivation; Sanofi; Tokai Pharmaceuticals; UpToDate
Research Funding - Bayer; Genentech; Janssen-Ortho; Medivation
Travel, Accommodations, Expenses - Dendreon; Janssen Oncology; Medivation; Tokai Pharmaceuticals
 
Amanda Fredericks Pace
Employment - Covidien (I); Millennium (I)
Consulting or Advisory Role - On Q Health
 
Kathryn Dumas
No Relationships to Disclose
 
Jeffrey G. Supko
Employment - Sanofi (I)
Consulting or Advisory Role - Debiopharm Group; Millennium
 
Katherine A. Zukotynski
No Relationships to Disclose
 
Brandon David Bernard
No Relationships to Disclose
 
Mark Pomerantz
No Relationships to Disclose
 
Aymen Elfiky
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi